Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Bacterium or component thereof or substance produced by said...
Reexamination Certificate
2011-07-26
2011-07-26
Kam, Chih-Min (Department: 1656)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Bacterium or component thereof or substance produced by said...
C424S236100, C435S069100, C435S069700, C435S252700, C514S012200, C530S350000, C536S023200
Reexamination Certificate
active
07985411
ABSTRACT:
Compositions comprising activatable recombinant neurotoxins and polypeptides derived therefrom. The invention also comprises nucleic acids encoding such polypeptides, and methods of making such polypeptides and nucleic acids.
REFERENCES:
patent: 4683202 (1987-07-01), Mullis
patent: 4800159 (1989-01-01), Mullis
patent: 5919665 (1999-07-01), Williams
patent: 5939070 (1999-08-01), Johnson et al.
patent: 5989545 (1999-11-01), Foster et al.
patent: 6395513 (2002-05-01), Foster et al.
patent: 6461617 (2002-10-01), Shone et al.
patent: 6632440 (2003-10-01), Quinn et al.
patent: 6962703 (2005-11-01), Foster et al.
patent: 7052702 (2006-05-01), Duggan et al.
patent: 7132259 (2006-11-01), Dolly et al.
patent: 7192596 (2007-03-01), Shone et al.
patent: 7419676 (2008-09-01), Dolly et al.
patent: 2003/0180289 (2003-09-01), Foster et al.
patent: 2004/0071736 (2004-04-01), Quinn et al.
patent: 2006/0024331 (2006-02-01), Fernandez-Salas et al.
patent: 2006/0099672 (2006-05-01), Dolly et al.
patent: 2007/0259401 (2007-11-01), Dolly et al.
patent: 2008/0032930 (2008-02-01), Steward et al.
patent: 2008/0032931 (2008-02-01), Steward et al.
patent: 2008/0081355 (2008-04-01), Dolly et al.
patent: 2008/0161226 (2008-07-01), Steward et al.
patent: 2008/0161543 (2008-07-01), Steward et al.
patent: 2008/0182294 (2008-07-01), Dolly et al.
patent: 0359347 (1990-03-01), None
patent: WO 94/21300 (1994-09-01), None
patent: WO 95/32738 (1995-12-01), None
patent: WO 96/33273 (1996-10-01), None
patent: WO 98/07864 (1998-02-01), None
patent: WO 98/08540 (1998-03-01), None
patent: WO 99/17806 (1999-04-01), None
patent: WO 99/55359 (1999-11-01), None
patent: WO01-14570 (2001-03-01), None
patent: WO 2004/024909 (2004-03-01), None
patent: WO2004-024909 (2004-03-01), None
patent: WO 2005/023309 (2005-03-01), None
patent: WO 2006/027207 (2006-03-01), None
patent: WO 2006/059093 (2006-06-01), None
patent: WO 2006/059105 (2006-06-01), None
patent: WO2006/059113 (2006-06-01), None
Herreros et al, “C-Terminal Half of Tetanus Toxin Fragment C is Sufficient for Neuronal Binding and Interaction with a Putative Protein Receptor”, Biochemical Journal, vol. 347, No. Part 1, pp. 199-204, Apr. 1, 2001.
Rummel et al, “The Hcc-domain of botulinum neurotoxins A and B exhibits a singular ganglioside binding site displaying serotype specific carbohydrate interation”, Molecular Microbiology, pp. 631-643, Dec. 15, 2003.
Halpern et al, “Characterization of the receptor-binding domain of tetanus toxin”, Journal of Biological Chemistry, pp. 11188-11192, May 25, 1993.
U.S. Appl. No. 60/150,710, filed Aug. 25, 1999, Dolly et al.
U.S. Appl. No. 11/781,359, filed Jul. 23, 2007, Dolly et al.
U.S. Appl. No. 11/829,475, filed Jul. 27, 2007, Steward et al.
U.S. Appl. No. 11/832,108, filed Aug. 1, 2007, Steward et al.
U.S. Appl. No. 11/832,173, filed Aug. 1, 2007, Steward et al.
U.S. Appl. No. 11/833,142, filed Aug. 2, 2007, Steward et al.
U.S. Appl. No. 11/833,720, filed Aug. 3, 2007, Steward et al.
U.S. Appl. No. 11/834,068, filed Aug. 6, 2007, Steward et al.
U.S. Appl. No. 11/844,517, filed Aug. 24, 2007, Steward et al.
U.S. Appl. No. 11/844,546, filed Aug. 24, 2007, Steward et al.
U.S. Appl. No. 11/844,780, filed Aug. 24, 2007, Steward et al.
U.S. Appl. No. 11/844,850, filed Aug. 24, 2007, Steward et al.
U.S. Appl. No. 11/844,885, filed Aug. 24, 2007, Steward et al.
U.S. Appl. No. 11/844,899, filed Aug. 24, 2007, Steward et al.
U.S. Appl. No. 11/844,919, filed Aug. 24, 2007, Steward et al.
U.S. Appl. No. 11/844,929, filed Aug. 24, 2007, Steward et al.
U.S. Appl. No. 11/845,167, filed Aug. 27, 2007, Steward et al.
U.S. Appl. No. 11/845,185, filed Aug. 27, 2007, Dolly et al.
U.S. Appl. No. 11/845,252, filed Aug. 27, 2007, Steward et al.
U.S. Appl. No. 11/845,284, filed Aug. 27, 2007, Steward et al.
U.S. Appl. No. 11/845,320, filed Aug. 27, 2007, Steward et al.
U.S. Appl. No. 11/845,345, filed Aug. 27, 2007, Steward et al.
U.S. Appl. No. 11/845,466, filed Aug. 27, 2007, Steward et al.
U.S. Appl. No. 11/962,812, filed Oct. 29, 2007, Dolly et al.
U.S. Appl. No. 11/845,157, filed Aug. 27, 2007, Steward et al.
Borodic et al, “Pharmacology and Histology of the Therapeutic Application of Botulinum Toxin Application of Botulinum Toxins”, pp. 119-157 (1994).
Tonello et al, “Tetanus and Botulinum Neurotoxins a Novel Group of Zinc-Endopeptidases”, Intracellular Protein Catabolism, Adv. Exp. Med. & Biol. 389, pp. 251-260 (1996).
Li, Yan et al., “A Single Mutation in the Recombinant Light Chain of Tetanus Toxin Abolishes Its Proteolytic Activity and Removes the Toxicity Seen After Reconstitution with Native Heavy Chain”,Biochemistry(1994), 33(22), 7014-20 CODEN: Bichaw; Issn: 0006-2960: pp. 7014-7020.
Coffield et al., “The Site and Mechanism of Action of Botulinum Neurotoxin”,Neurological Disease and Therapy, pp. 3-13, 25 (Jankovic J. & Hallett M. eds. 1994).
Foran et al, “Botulinum Neurotoxin Cl Cleaves both Syntaxin and SNAP-25 in Intact and Permeabilized Chromaffin Cells: Correlation with Its Blockade of Catecholamine Release”, Biochem. 35: pp. 2630-2636 (1996).
Dolly et al, “Probing the process of transmitter release with botulinum and tetanus neurotoxins” Seminars in Neuroscience, 6(3): pp. 149-158 (1994).
Zhou et al, “Expression and Purification of the Light Chain of Botulinum Neurotoxin A: A Single Mutation Abolishes Its Cleavage of SNAP-25 and Neurotoxiicity after Reconstruction with the Heavy Chain”, Biochemistry 34: pp. 15175-15181 (1995).
Lacy et al, “Crystal structure of botulinum neurotoxin type A and implications for toxicity” Nature Struct. Biol. Oct; 5 (10): pp. 898-902 (1998).
Kurazono et al, “Minimal Essential Domains Specifying Toxicity of the Light Cahins of Tetanus Toxin and Botulinum Neurotoxin Type A”, J. Biol. Chem.: pp. 14721-14729 (1992).
Smith et al, “Mutagenesis at a Specific Position in a DNA Sequence”, J. Biol. Chem. 253: No. 18, Sep. 25 issue, pp. 6651-6560 (1978).
Li et al, “Expression and Characterization of the Heavy Chain of Tetanus Toxin: Reconstruction of the Fully-Recombinant Dichain Proetin in Active Form”, J. Biochem. 125: pp. 1200-1208 (1999).
Chan Kuo Chion
Dolly J. Oliver
Li Yan
Abel Kenton
Allergan Inc.
Condino Debra
Kam Chih-Min
LandOfFree
Activatable recombinant neurotoxins does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Activatable recombinant neurotoxins, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Activatable recombinant neurotoxins will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2664923